Nurse awarded medal by King for Gaza aid
A nurse in her 70s says she has no plans to stop working after winning an award from King Charles for her life-saving work in Gaza.
Chris Hunter travelled twice to Gaza as a volunteer to deliver frontline aid with UK-Med and described the mass casualties she dealt with as a "conveyor belt of carnage" amongst the backdrop of nearby explosions.
Ms Hunter, who lives in Grimsby and is a theatre nurse at Diana Princess of Wales Hospital, was presented with the Humanitarian Medal at Buckingham Palace.
"I know my family would prefer I just put my feet up and started knitting or something – but I'd far rather help stitch up patients who need our help in Gaza," she said.
The field hospitals where she worked in Al Mawasi and Deir El Balah, established with Foreign, Commonwealth & Development Office (FCDO) funding, have treated more than 300,000 patients as part of the UK Government's humanitarian response to the Israel/Gaza crisis.
Ms Hunter served with the Queen Alexandra's Royal Army Nursing Corps for 32 years which took her to places such as Bosnia, Kosovo, Iraq and Afghanistan.
She said she has "no plans to put her feet up" and is awaiting news from UK-Med regarding another deployment to Gaza or Ukraine.
Ms Hunter said: "I know I am elderly and aged, but I just feel as though I've got so much to offer.
"I have a lot of experience and skills which are best used supporting people who really need our help in Gaza.
"You are in that wooden box for a long time when you die, so I am trying to make the most of being fit and healthy."
Foreign Secretary David Lammy said: "This new medal recognises the incredible dedication and selfless service of individuals on the frontline of the UK's responses to some of the world's most devastating crises."
Listen to highlights from Lincolnshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
Medal recognises Gaza work as valuable, medic says
Nurse honoured with humanitarian medal from King
Deadly floods medic first to win new King's medal
UK-Med
Foreign, Commonwealth & Development Office
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
42 minutes ago
- Medscape
Mavacamten Showing Real-World Success in Treating oHCM
MANCHESTER — Mavacamten (Camzyos, Bristol Myers Squibb) continues to show promising results in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a consultant cardiologist said at the recent British Cardiovascular Society Annual Conference 2025. William Jenkins, a consultant cardiologist at the Royal Infirmary of Edinburgh, said that real world outcomes mirror those from clinical trials, including EXPLORER and VALOR-HCM. High Rates of Symptom Improvement Notably, data from three UK centres showed that about 70%-80% of patients experienced symptomatic improvement with mavacamten treatment. In addition, 90% saw a 30mmHg drop in the left ventricular outflow tract (LVOT) gradient – considered a significant reduction in obstruction. William Jenkins Although patients initially required 'very intense echocardiographic surveillance', Jenkins said 'it gets much easier' after the first few months of treatment. 'I think our reliance upon echocardiography will probably reduce as we get more experience with this,' he told Medscape News UK . A First-in-Class Therapy Mavacamten, a cardiac myosin inhibitor, is the first drug of its kind. It works by normalising contractility, reducing dynamic LVOT obstruction, and improving cardiac filling pressures in people with HCM. 'HCM is something that develops over decades,' Jenkins said. 'You can develop symptoms early, but you can have those symptoms for a really long time before you go on to develop other things like abnormal heart rhythms, heart failure, or dying suddenly.' He added that although oHCM is considered rare, many patients could benefit from treatment. Managing HCM still falls within general cardiology in some centres, Jenkins noted, raising concerns that patients may not be reviewed as frequently as needed. 'People live with it for years and years — if not decades — before they develop any of the end stage features of HCM,' Jenkins said. 'They can become very adapted to their symptoms.' Patient Advocacy and Experience Hypertrophic cardiomyopathy affects around 1 in 500 people in the UK and US, with about two thirds of cases involving obstruction. Katharine McIntosh, head of research and policy at Cardiomyopathy UK, told Medscape News UK that mavacamten had been a 'cause for excitement' among patients. 'It's the first big cardiomyopathy-specific drug.' McIntosh expressed frustration at the slow rollout of the drug, which was recommended for NHS use in England and Wales in 2023 and in Scotland in 2024. 'It's at the point now where one would have thought that everyone who should be on it would be getting onto it. But that's just not been the case,' she said. A recent Cardiomyopathy UK survey found that patients who accessed mavacamten were 'very positive' about its effects. Respondents described it as 'life changing' and felt like they had been given their lives back, McIntosh said. Challenges Facing Widespread Use One barrier is that mavacamten must be prescribed and monitored by specialists experienced in treating cardiomyopathies – resources not available at all centres. Prescribing guidance states that patients require echocardiography before and at regular intervals after starting treatment. Genetic testing for Cytochrome P450 (CYP) 2C19 (CYP2C19) is also needed to guide dosing. Long-Term Outlook Jenkins said that three key issues must be considered before prescribing mavacamten: Close early monitoring is needed, as the drug can cause left ventricular systolic dysfunction. CYP2C19-related drug interactions require pharmacy input. Counselling is essential due to potential foetal toxicity risks. 'Most people tolerate this [drug] very well', he said. After the initial 12-week period, follow-up can be reduced to every 3-6 months. 'This is an indefinite medication for a lot of people' Jenkins said. However, with an estimated annual cost of almost £14,000 per patient, he stressed the need for careful initial use. 'Right now, the indication is for symptomatic, severe LVOT obstruction,' he said. However, 'there's no reason in the long-term why this shouldn't become first-line'. Whether mavacamten offers benefit for oHCM patients without obstruction remains unclear. Jenkins has acted as a consultant to BMS and AstraZeneca. McIntosh had no conflicts of interest to disclose.
Yahoo
2 hours ago
- Yahoo
Families to benefit from £2m support plan
Families in Rotherham are set to benefit from a new £2m plan aimed at improving support for children and parents before problems reach crisis point. At a meeting on Monday, Rotherham Metropolitan Borough Council's cabinet approved the next phase of its Family Help Strategy, which is part of a national push to offer earlier, more joined-up help to struggling families. The money will be used to bring services like social care, education, health and the police closer together, to try and stop families from falling through the cracks. Work on the transformation will begin immediately, with updates expected in the autumn, the council said. The changes aim to make it easier for families to get the right help at the right time, whether that is support with parenting, mental health, school attendance or other challenges, the Local Democracy Service reports. The plan includes the creation of multi-agency teams made up of social workers, education staff, health professionals and others who will work together to offer tailored, practical support before problems escalate. Families will also be more involved in shaping their own support, with a stronger role for extended family networks and a focus on building resilience at home. During the meeting, Victoria Cusworth, cabinet member for children and young people, said: "The funding is targeted at service transformation activity [and] increasing direct delivery of family help. "This is about enabling families to access the right help at the right time, and from the right people, reducing the need for statutory intervention and giving children the best possible start in life." Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North New hub aims to provide support for families Guides on parenting skills available for families Rotherham Council Local Democracy Reporting Service
Yahoo
3 hours ago
- Yahoo
‘Boil in the bag' funerals could be introduced in UK after European roll-out in Ireland
"Boil in a bag" funerals - already used widely in America - could soon be made available across the UK. This environmentally friendly, yet controversial, way to say your final goodbyes to a loved one has already been rolled out in Ireland back in 2023 and could come to the UK next. This unusual method, officially known as water cremation or alkaline hydrolysis, is currently effectively banned in the UK, but could well get the legal go-ahead following the independent Law Commission's new consultation into funerary methods. READ MORE: Dad, 32, who flew to Turkey for family holiday dies hours after being escorted off plane READ MORE: Met Office verdict on UK heatwave this WEEK as temperatures to climb to 29C Already available across 30 US states, as well as Canada and South Africa, the first European water cremation facility, or resomation, opened its doors in early 2023 in Navan, Co Meath, Ireland. Traditional burials can lead to embalming fluid seeping into the grave soil, while each gas-powered fire cremation releases around 245kg of CO2 into the atmosphere, according to UK-based cemetery and crematorium development the CDS Group. By comparison, figures from Resomation Ltd, the founding body for alkaline hydrolysis, show just 28kg of CO2 is released into the atmosphere per water cremation. Unlike conventional cremations, these eco-friendly farewells, which take between three to four hours, also don't release harmful mercury emissions into the atmosphere. But you might be wondering how the process actually works. Well, first the body is loaded into the alkaline hydrolysis machine, which calculates the amount of water and potassium hydroxide required. The machine locks and an alkaline solution fills the pressurised tank, which is gently heated to 152C. The remains get broken into their chemical components - amino acids, peptides, sugars and salt - leaving behind a liquid that is then cooled in another tank until sterile and free from any remaining tissue or DNA. Around 330 gallons of brown-coloured liquid will be washed down the drain, while the softened bones are ground to powder in a reducer, and presented in an urn to the grieving family. In 2017, Wired journalist Hayley Campbell described the process in colourful detail after seeing a resomator in action at the University of California, Los Angeles (UCLA). Hayley wrote: "Over the course of up to four hours, the strong alkaline base causes everything but the skeleton to break down to the original components that built it: sugar, salt, peptides and amino acids; DNA unzips into its nucleobases, cytosine, guanine, adenine, thymine. "The body becomes fertiliser and soap, a sterile watery liquid that looks like weak tea. The liquid shoots through a pipe into a holding tank in the opposite corner of the room, where it will cool down, be brought down to an acceptable pH for the water treatment plant, and be released down the drain." Noting that "it's not actually that terrible", Hayley revealed: "The human body, liquefied, smells like steamed clams." Highlighting why this process is still a bit of a taboo in an interview with The Telegraph, Dr Lian Lundy, a wastewater specialist from Middlesex University, explained: "Some people view it as basically mixing up my loved one with poo in the sewer and they don't like that. "But there's a lot that goes into the sewer that we don't really think about – waste from mortuaries and hospitals and all sorts of things that we don't know about – so from that perspective, it's not really any different."
